Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor and Crushed Ticagrelor in STEMI (CANTIC)
NCT03247738Phase 4Completed
- Sponsor
- University of Florida
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cangrelor in ST-elevation myocardial infarction (STEMI), sponsored by University of Florida. Primary endpoint: Platelet Reactivity Measured by VerifyNow P2Y12 Reaction Units at 30 minutes. Started Nov 2017; status: completed.
02
Drugs
cangrelor
03
Conditions
ST-elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03247738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247738.